Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01901809 · ClinicalTrials.gov registry record · Phase 4
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
A Phase 4 study of Heart Failure, Diastolic, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT01901809 is a Phase 4 study of Heart Failure, Diastolic that has completed, run by Johns Hopkins University. The registered enrollment target is 90 participants, below the 314-participant average among 14 other Heart Failure, Diastolic trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01901809, a Phase 4 study of Heart Failure, Diastolic, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with heart failure with reduced ejection fraction (HFREF). Patients with HFPEF are often preload dependent and despite admission to the hospital for acute decompensated heart failure (ADHF), are typically difficult to diurese due to the development of acute kidney injury. No studies have been performed evaluating treatment strategies for these patients. The investigators hypothesize that changing the method of diuresis and/or the addition of low-dose dopamine for the treatment of ADHF in patients with HFPEF will reduce renal injury, resulting in a shorter length of stay, and decrease hospital readmissions over the ensuing year. This trial will randomize patients to either bolus or continuous infusion furosemide and then to either dopamine or no dopamine. The primary endpoint will be renal function at 72 hours as measured by change in Glomerular Filtration Rate (GFR). Secondary endpoints for readmission, functional capacity, quality of life, and amount of diuresis will also be collected.
Conditions Studied
Interventions
- DRUG Dopamine
- DRUG Furosemide
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01901809
The ClinicalTrials.gov registry entry for NCT01901809 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 314-participant average among 14 other Heart Failure, Diastolic trials with a reported enrollment target (71% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure, Diastolic appearing as the primary indexed condition, and to 2 interventions - of which Dopamine is the first listed.
NCT01901809 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01901809 about?
NCT01901809 is a clinical study titled "Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction". Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with heart failure with reduced ejection fraction (HFREF). Patients with HFP...
What is the current status of trial NCT01901809?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2013-08. Estimated completion is 2018-05.
What conditions does trial NCT01901809 study?
This clinical trial studies the following conditions: Heart Failure, Diastolic.
What interventions are being tested in trial NCT01901809?
The interventions under investigation include: Dopamine (DRUG), Furosemide (DRUG).
Who is sponsoring clinical trial NCT01901809?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01901809 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure, Diastolic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
COMPLETED · Phase 4
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Assessment of Left Ventricular Filling Pressure by Applying Artificial Intelligence Algorithms to Left Atrial Speckle-tracking Echocardiography
RECRUITING
-
Associations Between the Microbiome, Skeletal Muscle Perfusion, and Fitness Status
RECRUITING
-
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.